About this trial
The purpose of this trial is to evaluate whether adding the drug rigosertib to the patient’s doctor’s choice (standard of care treatment) works better and is as safe as the doctor’s choice.
Patients with Myelodysplastic Syndrome After Failure of drugs called Hypomethylating Agents (azacitidine (AZA) or decitabine (DEC)), 18 to 79 years of age, who have been treated with hypomethylating agents for </= 9 months.
Where’s this trial being run?Cork University Hospital, Tallaght University Hospital, University Hospital Galway, and University Hospital Waterford
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.Print this page
For more detailed informationClick Here
A Phase III International Randomised Controlled Study of Rigosertib versus Physicians Choice in MDS After Failing A Hypermethylating Agent.
|Principal Investigator:||Prof Helen Enright (Tallaght Hospital)|
Global: October 2015
Ireland: May 2016
|Global Recruitment Target:||225|
|Ireland Recruitment Target:||12|